Antipruritic therapy as main component of improving quality of life of patients with dermatoses
https://doi.org/10.33667/2078-5631-2020-6-6-10
Abstract
Itchy skin, a symptom of various diseases, present in 54.4 % of patients with skin pathologies, is a rather difficult task when choosing a therapy.
Material and methods. Under observation were 45 patients (27 women and 18 men) with various dermatoses, accompanied by itching. All patients received Neotanin therapy (cream and spray) with standard topical therapy. Efficiency assessment was carried out taking into account the indices Prurindex, BRS, dermatological status indices for each nosology (SCORAD, EASI, PASI), and DIC.
Results. In patients with idiopathic skin itching, Prurindex decreased by 100 % by the end of 3rd weeks, BRS – by 96.8 %. In atopic dermatitis, the SCORAD index decreased by 78.3 %, BRS index reduced by 91.9 %, Prurindex index decreased by 95.4 %. With eczema, the EASI index decreased by 96.1 %, the BRS and Prurindex index were reduced by 100 %. In psoriasis, the PASI index decreased by 86.5 %, BRS index – by 90.8 %, Prurindex index – by 94.2 %.
Conclusions. The use of the topical Neotanin as monotherapy for idiopathic pruritus, as a part of comprehensive treatment for atopic dermatitis, eczema, psoriasis, significantly improves the quality of life of patients.
About the Authors
L. S. Kruglova
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Russian Federation
Moscow
N. O. Pereverzina
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Russian Federation
Moscow
Yu. A. Kovalenko
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Russian Federation
Moscow
References
1. Weisshaar E. Epidemiology of Itch. Curr Probl Dermatol. 2016; 50: 5–10.
2. Дерматология Фицпатрика в клинической практике. Издание второе. Под ред. Потекаева Н. Н., Львова А. Н., Адаскевича В. П., Романова Д. В. М.: Издательство Панфилова; 2019; 1271–1274.
3. Yasutomo I Interleukin-33 in atopic dermatitis. J Dermatol Sci. 2019; 96 (1): 2–7.
4. Deleanu D, Nedelea I Biological therapies for atopic dermatitis: An update (Review). Experimental and therapeutic medicine. 2019; 17: 1061–1067.
5. Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, Nagase H Involvement ofcentral mu-opioid system in the scratching behavior inmice and the suppression of it by the activation ofkappa-opioid system. Eur J Pharmacol. 2003; 477: 29–35.
6. Mochizuki H, Schut C, Nattkemper L, Yosipovitch G. Brain mechanism of itch in atopic dermatitis and its possible alteration through non-invasive treatments. Allergology International. 2017; 66 (1): 14–21.
7. Hassan I, Haji ML Understanding itch: An update on mediators and mechanisms of pruritus. Indian J Dermatol Venereol Leprol. 2014; 80 (2): 106–14.
8. Oswald K. Atopic dermatitis: dupilumab and crisaborole could herald a new era in treatment. The Pharmaceutical Journal. Accepted February 23, 2017. www.pharmaceutical-journal.com/news-and-analysis/features/atopic-dermatitis-dupilumab-and-crisaborole-could-herald-a-new-era-in-treatment/20202337.article.
9. Yosipovitch G, Rosen JD, BS, Hashimoto T. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018; 142 (5): 1375–1390.
10. Inagaki N, Shiraishi N, Igeta K, Nagao M, Kim JF, Chikumoto T, Itoh T, Katoh H, Tanaka H, Nagai H. Depletion of substance P, a mechanism for inhibition of mouse scratching behavior by tacrolimus. Eur J Pharmacol. 2010; 25; 626 (2–3): 283–9.
11. Hoy SM Crisaborole Ointment 2 %: A Review in Mild to Moderate Atopic Dermatitis. Am J Clin Dermatol. 2017; 18 (6): 837–843.
12. Elmariah S Adjunctive Management of Itch in Atopic Dermatitis. Dermatol Clin. 2017; 35 (3): 373–394.
13. Misery L, Huet F, Gouin O, Sta S, Deleuran M Current pharmaceutical developments in atopic dermatitis. Curr Opin Pharmacol. 2019; 46: 7–13.
14. Заславский Д. В., Туленкова Е. C., Монахов К. Н., Холодилова Н. А., Кондратьева Ю. С., Тамразова О. Б., Немчанинова О. Б., Гулиев М. О., Шливко И. Л., Торшина И. Е. Экзема: тактика выбора наружной терапии. // Вестник дерматологии и венерологии. 2018; 94 (3): 56–66.
15. Карпова О. А. Неотанин – снятие зуда при инфекциях кожи. // Дерматология в России. – 2018. – № S 2. – С. 22–23.
16. Стадникова А. С., Тамразова О. Б. Применение неотанина в терапии атопического дерматита у детей грудного возраста. // Дерматология в России. – 2017. – № S 1. – С. 88–88.
17. Монахов К. Н., Холодилова Н. А. Особенности ведения пациенток с обострением атопического дерматита на фоне беременности. // Дерматология / Аллергология. – 2018. – С. 47.
18. Холодилова Н. А., Монахов К. Н. Новое в коррекции кожного зуда у пациентов с зудящими дерматозами. // Клиническая дерматология и венерология. – 2019. – Т. 18. – № 4.
Review
For citations:
Kruglova L.S., Pereverzina N.O., Kovalenko Yu.A. Antipruritic therapy as main component of improving quality of life of patients with dermatoses. Medical alphabet. 2020;(6):6-10. (In Russ.) https://doi.org/10.33667/2078-5631-2020-6-6-10
Views:
767
Email this article 